SAR-443579

N/A

Report date: 2025/08/23 20:00:08

Base Information

Drug NameSAR-443579
Drug Alias NameSAR-443579SAR443579IPH6101IPH-6101SAR'579
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionNatural cytotoxicity triggering receptor 1 inhibitorsLow affinity immunoglobulin gamma Fc region receptor III-A agonistsInterleukin-3 receptor subunit alpha inhibitors
TargetsNatural cytotoxicity triggering receptor 1Low affinity immunoglobulin gamma Fc region receptor III-AInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesHematologic Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsNew Zealand +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis Recherche & Developpement
Inactive CompaniesSanofiSanofi (China) Investment Co Ltd
Active IndicationsHematologic Diseases
Inactive IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 

Other Information

ATC CodeN/A
Related LinksN/A